Statements (96)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Medi_Gene_AG
Genentech's RNA platform |
| gptkbp:approves |
gptkb:FDA
gptkb:WHO gptkb:EMA |
| gptkbp:ceo |
gptkb:Özlem_Türeci
gptkb:Uğur_Şahin |
| gptkbp:clinical_trial |
ongoing
Phase 3 COVID-19 vaccine trials HIV vaccine trials cancer therapies vaccine for malaria for cancer vaccines |
| gptkbp:collaborations |
gptkb:Genentech
gptkb:Sanofi gptkb:Moderna gptkb:Fosun_Pharma government agencies non-profit organizations academic institutions international organizations pharmaceutical companies biotech companies foundations clinical research organizations |
| gptkbp:distribution |
gptkb:governments
global health organizations cold chain logistics NG Os equitable access initiatives |
| gptkbp:dosage_form |
over 2 billion
|
| gptkbp:employees |
over 1,000
over 1,500 |
| gptkbp:focus_area |
m RNA technology
|
| gptkbp:founded |
gptkb:2008
|
| gptkbp:founder |
gptkb:Özlem_Türeci
gptkb:Uğur_Şahin |
| gptkbp:headquarters |
gptkb:Mainz,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biontech
|
| gptkbp:incubation_period |
less than a year
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:innovation |
m RNA platform
adaptive clinical trials |
| gptkbp:invention |
over 1,000
|
| gptkbp:is_effective_against |
95% (COVID-19)
95% against COVID-19 high efficacy against variants |
| gptkbp:is_vulnerable_to |
gptkb:rapid_response
gptkb:Comirnaty monitored reduced hospitalizations collaborative research efforts herd immunity reduced deaths global pandemic response extensive clinical trials |
| gptkbp:market_cap |
$50 billion (2021)
$40 billion (2021) |
| gptkbp:notable_products |
BN T162b2
|
| gptkbp:open_to_public |
gptkb:NASDAQ
|
| gptkbp:partnership |
gptkb:temple
gptkb:Sanofi gptkb:Pfizer gptkb:Cure_Vac international collaborations Pfizer-Bio N Tech |
| gptkbp:produced_by |
scalable manufacturing
|
| gptkbp:provides |
government contracts
|
| gptkbp:receives_funding_from |
$1 billion (2021)
|
| gptkbp:research |
ongoing
infectious diseases therapeutics for autoimmune diseases novel delivery systems |
| gptkbp:research_areas |
gptkb:University_of_Mainz
infectious diseases cancer immunotherapy |
| gptkbp:research_focus |
personalized cancer therapies
|
| gptkbp:revenue |
$18.9 billion (2021)
|
| gptkbp:scientific_name |
gptkb:Comirnaty
|
| gptkbp:side_effect |
mild to moderate
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:storage |
-70 degrees Celsius
-70° C standard refrigerator temperatures |
| gptkbp:symbol |
gptkb:BNTX
|
| gptkbp:targets |
gptkb:SARS-Co_V-2
|
| gptkbp:technology |
lipid nanoparticles
RNA-based therapeutics platform technology next-generation vaccines |
| gptkbp:trigger_type |
gptkb:vaccine
|
| gptkbp:bfsParent |
gptkb:Cure_Vac's_COVID-19_vaccine_trial
|
| gptkbp:bfsLayer |
5
|